Moreover, our group has previously identified metabolic addiction to β-catenin-GS-mTOR axis in β-catenin-mutated HCC and evaluated mTOR inhibitor (e.g., rapamycin, everolimus) response in multiple preclinical models of β-catenin-mutated HCC. This evidence concerns the gene MTOR and hepatocellular carcinoma.